RISPERIDONE INJECTABLE LONG-ACTING TREATMENT VS OTHER ORAL ANTIPSYCHOTICS IN FIRST EPISODE PSYCHOSIS: ONE YEAR LONGITUDINAL STUDY

2010 ◽  
Vol 117 (2-3) ◽  
pp. 495 ◽  
Author(s):  
Rafael Segarra ◽  
Natalia Ojeda ◽  
Jon Garcia ◽  
Javier Peña ◽  
Elena Bravo ◽  
...  
2006 ◽  
Vol 86 (1-3) ◽  
pp. 71-75 ◽  
Author(s):  
Jean Addington ◽  
Ana Chaves ◽  
Donald Addington

2011 ◽  
Vol 126 (1-3) ◽  
pp. 77-80 ◽  
Author(s):  
Javier Peña ◽  
Natalia Ojeda ◽  
Rafael Segarra ◽  
Jose Ignacio Eguiluz ◽  
Jon García ◽  
...  

2019 ◽  
Vol 45 (Supplement_2) ◽  
pp. S349-S349
Author(s):  
Marie-Michelle Tremblay ◽  
Sarah-Maude Rioux ◽  
Charlie Fraser ◽  
Anne-Pierre Bouffard ◽  
Sophie L’Heureux ◽  
...  

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S85-S86
Author(s):  
Maija Walta ◽  
Heikki Laurikainen ◽  
Reetta-Liina Armio ◽  
Tiina From ◽  
Raimo K R Salokangas ◽  
...  

Abstract Background Attrition rates and sampling bias in controlled clinical studies are a concern when evaluating the relevance of the results to a specific patient population in a real-life clinical / treatment setting. Dropout rates in studies on psychotic disorders are high and many eligibility criteria may lead to bias in study samples. We wanted to analyze how representative are the patient samples typically included in first-episode psychosis studies such as the Turku Early Psychosis (TEPS) study by using a platform of 3772 consecutive admissions to clinical psychiatric services of Turku Psychiatry. Methods TEPS study was started in 2011 as a part of a larger study on psychosis treatment processes in Turku Psychiatric services. Each patient, inpatient and outpatient, went through initial clinical screening by the treatment group which was followed by a structured evaluation if the screen for first-episode psychosis was positive. Between Oct 2011 and June 2016 there were 195 patients with first-episode psychosis (FEP) suitable to the TEPS study. Of them 102 were willing and 93 were not willing to participate or were not reached in a baseline structured evaluation. Using patient records, we compared if these two groups differed in terms of clinical variables, treatment or prognosis during a 1-year follow-up. Time of hospital stay, involuntary vs. voluntary admission, coercive measures during the hospital care, re-hospitalizations and drop-out from the clinical care during the follow-up were used as outcomes. Results Non-participating (NTP) group had higher rate of involuntary care than participating (TP) group (70 % vs 62 %) as well as higher rate of coercion during the treatment and higher rate of re-admissions during the follow-up than the TP group (36 % vs 22 % and 41 % vs 34 %, respectively) but these differences did not reach statistical significance. During the one-year follow-up NTP group had a significantly higher rate of dropping out from the clinical care than participating TP group (48 % vs 30 %, p=0.01). NTP group had also higher rate of dropping out of clinical treatment mainly because of patient non-adherence (33 % vs 16 %, p=0.03). Discussion Nearly half (47 %) of the intent-to-study FEP patients were not reached or declined to participate in our study. Non-participating patients had a slightly more severe illness and poorer treatment adherence during one-year follow-up. The clinical differences were not as marked as we expected. E.g. involuntary care, inpatient care and more coercion during the follow-up were not significantly different between NTP and TP groups. Nevertheless, the data suggest considerable differences between participating and non-participating patients with first-episode psychosis which should be taken in to account when evaluating the generalizability of the results for an unselected group of psychotic patients in ‘real-life’ clinical care.


2016 ◽  
Vol 33 (S1) ◽  
pp. s249-s250
Author(s):  
A.L. Gonzalez Galdamez ◽  
M.D. Piqueras Acevedo ◽  
M.R. Raposo Hernández ◽  
I. Martínez Pérez ◽  
P. Manzur Rojas ◽  
...  

The aim is to describe the experience of treatment with Paliperidone Palmitate long acting injection (PP) in patients with psychotic active clinic, whether diagnoses with schizophrenia or in patients with the first episode psychosis, as well as to reflect the improvement in the control of the symptoms that the patients can improve increasing the dose.MethodsWe have done a descriptive study of 34 patients hospitalized in psychiatry between January and July 2015 for psychotic active clinic who started treatment with PP or the previous dose was increased.Results91.2% of patients admitted for acute exacerbation of their usual pathology and 8.8% for a first episode psychosis. In the CGI scale, all the patients admitted scored as severe or markedly ill; going mostly mildly ill at discharge. For 55.9% of patients, the treatment was changed to PP, 29.4% of the dose was increased PP and 14.7% antipsychotic treatment was started with PP. Among patients change treatment, the main reason was non-adherence (47.4%). 70.6% of our patients were discharged with PP as only antipsychotic and 29.4% which was discharged with another antipsychotic, the most frequent association was of PP with Quetiapine (80%).ConclusionsPP is a highly effective medicament in the treatment of the schizophrenia that improves the adherence to the treatment, so in our experience and we consider it a medicament to be considered in the early stages of the disease. According to our experience and there are patients who can benefit from better control of symptoms adjusting the dose individually.Disclosure of interestThe authors have not supplied their declaration of competing interest.


Sign in / Sign up

Export Citation Format

Share Document